drugset
Drugs / mRNA-1645-N332GT5
last change Dec 2025 re-read 3 minutes ago

mRNA-1645-N332GT5

Messenger RNA (mRNA)

Developed for
HIV infectious disease
Investigated by
Bill and Melinda Gates Foundation · International AIDS Vaccine Initiative · ModernaTX, Inc. · National Institute of Allergy and Infectious Diseases (NIAID) · The Scripps Research Institute

Trials 1

today NCT06694753 · Ph 1
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06694753 Dec 2025 → Dec 2026 expected HIV infectious disease International AIDS Vaccine Initiative Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as mRNA-1645-N332GT5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694753 ↗
Modality Messenger RNA (mRNA) “N332-GT5 gp151 will be delivered using an mRNA-LNP platform.” NCT06694753 ↗
Route Intramuscular “To be administered by IM injection at doses of 10 or 30 mcg.” NCT06694753 ↗